TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Time to healing of deep heel fissures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sensitivity and specificity for identifying air trapping and consolidation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Mycobacterium avium colony count in sputum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in time to positivity of Mycobacterium avium growth in the Mycobacterial Growth Indicator Tube (MGIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lung Clearance Index 2.5% (LCI 2.5%) Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: proportion of patient's time spent at home the last 3 months of life
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: carers' health related quality of life (HRQOL) 6 months after patient's death
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Dose-limiting toxicities of Grade 3 or greater
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in X4-tropic virus from baseline of 1 log10 relative luciferase units (rlu)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean Change in Composite Score from BACS Battery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Negative Predictive Value (NPV) in rectosigmoid
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement in surveillance intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine Equivalents Consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean IOP (Intraocular Pressure)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Adverse events measurement
Endpoint domain: Adverse events/effects
Primary endpoint: Heart Failure-related Urgent Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Significant Increase in Left Ventricular End Systolic Volume Index (LVESVI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Optimal workload
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: confirmed remission rate
Endpoint domain: Mortality/survival
Primary endpoint: progression free survival (PFS)
Endpoint domain: Mortality/survival
Primary endpoint: liver biochemistry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: histological findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nocturnal oxygen desaturation index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Team level adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Individual level adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cumulative incidence of Net adverse clinical event
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants Who Experience Optimal Imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Rotator Cuff Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Arthroscopical OA grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complications of knee arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications of hip arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications of shoulder arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications of ankle arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Complications of elbow arthroplasty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Post operative otorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tympanostomy tube blockage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Presence of protozoans
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Lesion to Normal tissue Ratio (LNR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in dyspepsia symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Salivary IL-34 level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary OPG level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Salivary RANKL level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum IL-34 level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum OPG level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum RANKL level (pg/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in MoCA test scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Victorian Institute of Sports Assessment-Achilles (VISA-A)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Seriousness, severity and frequency of treatment related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: accuracy of molecular stool test (Cologuard) and FIT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cost-effectiveness of stool-based surveillance strategies
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: life time health effects of stool-based surveillance strategies
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in diagnostic status and severity of social anxiety symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete evacuation of uterus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Safety of PLX51107 as measured by adverse events and serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: PT/INR values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Ongoing pregnancy rate to 8 weeks gestation
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of outcomes favoring the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fexofenadine Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fexofenadine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depression levels as measured by the CES-D Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Surgical Site Infection
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of Dyspnea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: survival to cardiac transplantation prior to 180 days
Endpoint domain: Mortality/survival
Primary endpoint: survival on device to 180 days
Endpoint domain: Mortality/survival
Primary endpoint: survival to 60 days after device removal
Endpoint domain: Mortality/survival
Primary endpoint: Plasma levels of cannabinoids and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cardiopulmonary fitness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Intra-variability of phenylalanine values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Prevention of urethral infection with N. gonorrhoeae
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of postoperative serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Optical density (ODs) of each slice
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in Pancreatitis Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in physical activity thermogenesis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in expression of circadian clock genes measured in whole blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in postprandial glycaemia following carbohydrate rich test breakfast and lunch over 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in postprandial insulinaemia following carbohydrate rich test breakfast and lunch over 4 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Clinical Improvement (TTCI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in the Sociocultural Attitudes towards Appearance Questionnaire-4, Affects by Media subscale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from Baseline in Rosenberg Self Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change from Baseline in Body Esteem Scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Incidence of adverse events attributable to the cellular immunotherapy product
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells based on DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: MTD of autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing TN/MEM-enriched T cells based on DLTs
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with grade 3 or 4 imaging-related toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline of pulse measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cytokine parameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area Under the Curve (AUC) at steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmin at steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax at steady-state
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Sedentary Activity
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Levels of amyloid beta 1-40 in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum observed plasma concentration (Cmax) of JNJ-54861911
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The number of volunteers who experience adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Voxel-wise Blood Oxygen Level Dependent (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Count of Participants With Serious and Non-Serious Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Objective Response Rate of Patients With Metastatic Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Passive leg raise responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Synovial Fluid Drug Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retained CBD stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Efficiency of inhibitory pain modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Documentation of therapy forms used
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Plasma nitrite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: post operative pain control
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety during the use of rufinamide and other anti-epileptic drugs
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Moderate or Severe COPD Exacerbations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Hoffmann's reflex amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in the patient's Spirometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in the patient's oximetry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in 6 min walk test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Multidimensional Scale of Perceived Social Support
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Fear of Intimacy Scale-friend version
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants Who Experienced At Least One or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Total weight loss percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Duration of dependency on intensive care (days in ICU)
Endpoint domain: Mortality/survival
Primary endpoint: Change in Lysis Time (LT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complication-free Rate at 6 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV Pacing Capture Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in QT(c) intervals
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Cmax,ss (maximum measured concentration of the analyte in plasma at steady state)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCτ,ss (area under the concentration-time curve of the analyte in plasma at steady state over a uniform dosing interval τ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of New Bone Mass Formed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quality of Bone Regeneration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Anti-influenza antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants With Alkaline Phosphatase (ALP) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle biopsy outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge about preeclamptic pregnancy care
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Pain score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Maximum tolerated dose of oral 3-AP
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Subjects Achieving Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in 6 Minute Walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in Bilateral Thigh Lean Mass Density
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Area Under the Curve (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Injection Site Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects achieving >50% increase in Factor VIII antigen levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage Change in Testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walking speed (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: stance duration (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: step length (change)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Death or re-hospitalization from HF
Endpoint domain: Mortality/survival
Primary endpoint: Percent change in intestinal permeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Progression-free survival status
Endpoint domain: Mortality/survival
Primary endpoint: modified Teachers Drooling Scale (% responding)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone microarchitecture of the distal radius
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Consistency of stools based on Bristol Stool Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of patients with an EWS >/= 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 2 hour postprandial blood glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to initiate a local treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Hot flash frequency and intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Buccal bone dimensional changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of ActiLady
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Participants With Treatment-emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical success (no recurrent pulmonary embolism, IVC occlusion or filter embolization)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Grade 3 or 4 Thrombocytopenia
Endpoint domain: Adverse events/effects
Primary endpoint: Percent Change in the Bionocularly Averaged Perimetric Mean Deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Hot flashes episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of biventricular pacing >95%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: tear film lipid layer thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total number of mechanical ventilation days
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change From Baseline in HbA1c (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Peak Plasma Concentration (Cmax) of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUCt) of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration versus time curve (AUC∞) of nicotine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in PSA serum levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fat Absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: skin prick test reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Relative Change From Baseline in Percent Predicted Forced Expiratory Volume in One Second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of participants with serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients achieving BASDAI 50
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average shoulder abduction measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Score Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Plasma Concentrations of sitaxsentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Curve of sitaxsentan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants who consent to donate organs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in headache intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: need to use analgesics within 24 hours after treatment
Endpoint domain: Adverse events/effects
Primary endpoint: Oocyte maturity rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Facial nerve function recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hepatic Metastasis Stabilization Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes